Newgenivf Group Limited Stock Current Ratio
| NIVF Stock | 0.67 0.02 2.90% |
Fundamental analysis of NewGenIvf Group allows traders to better anticipate movements in NewGenIvf Group's stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 1.05 | 1.12 |
NewGenIvf | Current Ratio | Build AI portfolio with NewGenIvf Stock |
NewGenIvf Group Limited Company Current Ratio Analysis
NewGenIvf Group's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current NewGenIvf Group Current Ratio | 1.12 |
Most of NewGenIvf Group's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NewGenIvf Group Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NewGenIvf Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for NewGenIvf Group is extremely important. It helps to project a fair market value of NewGenIvf Stock properly, considering its historical fundamentals such as Current Ratio. Since NewGenIvf Group's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewGenIvf Group's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewGenIvf Group's interrelated accounts and indicators.
Click cells to compare fundamentals
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
NewGenIvf Price To Sales Ratio
Price To Sales Ratio |
|
NewGenIvf Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewGenIvf Group's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewGenIvf Group could also be used in its relative valuation, which is a method of valuing NewGenIvf Group by comparing valuation metrics of similar companies.NewGenIvf Group is currently under evaluation in current ratio category among its peers.
NewGenIvf Fundamentals
| Return On Equity | 1.61 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | 3.81 % | ||||
| Operating Margin | (1.96) % | ||||
| Current Valuation | 6.12 M | ||||
| Shares Outstanding | 1.32 M | ||||
| Shares Owned By Insiders | 0.29 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Number Of Shares Shorted | 223.46 K | ||||
| Price To Book | 0.03 X | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 5.43 M | ||||
| Gross Profit | 970.96 K | ||||
| EBITDA | 24.26 K | ||||
| Net Income | (474.1 K) | ||||
| Total Debt | 3.03 M | ||||
| Book Value Per Share | 68.23 X | ||||
| Cash Flow From Operations | (8.26 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | 1,398 X | ||||
| Target Price | 75.0 | ||||
| Number Of Employees | 76 | ||||
| Beta | -0.092 | ||||
| Market Capitalization | 909.39 K | ||||
| Total Asset | 3.58 M | ||||
| Retained Earnings | (985.99 K) | ||||
| Working Capital | 452.39 K | ||||
| Net Asset | 3.58 M |
About NewGenIvf Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewGenIvf Group Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewGenIvf Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewGenIvf Group Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether NewGenIvf Group is a strong investment it is important to analyze NewGenIvf Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NewGenIvf Group's future performance. For an informed investment choice regarding NewGenIvf Stock, refer to the following important reports:Check out NewGenIvf Group Piotroski F Score and NewGenIvf Group Altman Z Score analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewGenIvf Group. If investors know NewGenIvf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewGenIvf Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.4 K | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
The market value of NewGenIvf Group is measured differently than its book value, which is the value of NewGenIvf that is recorded on the company's balance sheet. Investors also form their own opinion of NewGenIvf Group's value that differs from its market value or its book value, called intrinsic value, which is NewGenIvf Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewGenIvf Group's market value can be influenced by many factors that don't directly affect NewGenIvf Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewGenIvf Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewGenIvf Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewGenIvf Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.